Boston Partners
CLB icon

Boston Partners’s Core Laboratories CLB Stock Holding History

Boston Partners’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-27,100
Closed -$3.13M – 744
2017
Q1 		$3.13M Hold
27,100
– – ﹤0.01% 588
2016
Q4 		$3.25M Hold
27,100
– – ﹤0.01% 591
2016
Q3 		$3.04M Hold
27,100
– – ﹤0.01% 588
2016
Q2 		$3.36M Buy
27,100
+2,587
+11% +$312K ﹤0.01% 554
2016
Q1 		$2.76M Buy
24,513
+5,746
+31% +$597K ﹤0.01% 560
2015
Q4 		$2.04M Hold
18,767
– – ﹤0.01% 614
2015
Q3 		$1.87M Buy
+18,767
New +$2.04M ﹤0.01% 615

Other funds holding CLB

ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
WP
Wedgewood Partners St Louis, Missouri $484M AUM 16.04% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Boston Partners's CLB Position: Q2 2017 in Review

Boston Partners sold out of Core Laboratories (CLB) in Q2 2017, closing a stake of 27,100 shares — an estimated $3.13M sold.

Boston Partners first reported a position in CLB in Q3 2015 and held it in 7 quarters. The position peaked at $3.36M in Q2 2016. 360 funds tracked by Wall St. Rank hold CLB as of Q2 2017.

  • Boston Partners reported no remaining Core Laboratories position as of Q2 2017 after selling out during the quarter.
  • Boston Partners sold 27,100 Core Laboratories shares in Q2 2017, an estimated $3.13M.
  • Boston Partners first reported a position in Core Laboratories in Q3 2015 and held it in 7 quarters.
  • Boston Partners's Core Laboratories position peaked at $3.36M in Q2 2016.
  • 360 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2017.

Based on Boston Partners's 13F filing for Q2 2017, filed 2 Aug 2017.